BIOMAT Database Logo BIOMAT Database Logo

Adrenomedullin: a novel cardiovascular regulatory peptide. 1996

F W Hanna, and K D Buchanan
Wellcome Research Laboratories, Department of Medicine, Queen's University of Belfast, UK.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002320 Cardiovascular Physiological Phenomena Processes and properties of the CARDIOVASCULAR SYSTEM as a whole or of any of its parts. Cardiovascular Physiologic Processes,Cardiovascular Physiological Processes,Cardiovascular Physiology,Cardiovascular Physiological Concepts,Cardiovascular Physiological Phenomenon,Cardiovascular Physiological Process,Physiology, Cardiovascular,Cardiovascular Physiological Concept,Cardiovascular Physiological Phenomenas,Concept, Cardiovascular Physiological,Concepts, Cardiovascular Physiological,Phenomena, Cardiovascular Physiological,Phenomenon, Cardiovascular Physiological,Physiologic Processes, Cardiovascular,Physiological Concept, Cardiovascular,Physiological Concepts, Cardiovascular,Physiological Phenomena, Cardiovascular,Physiological Phenomenon, Cardiovascular,Physiological Process, Cardiovascular,Physiological Processes, Cardiovascular,Process, Cardiovascular Physiological,Processes, Cardiovascular Physiologic,Processes, Cardiovascular Physiological
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D053607 Adrenomedullin A 52-amino acid peptide with multi-functions. It was originally isolated from PHEOCHROMOCYTOMA and ADRENAL MEDULLA but is widely distributed throughout the body including lung and kidney tissues. Besides controlling fluid-electrolyte homeostasis, adrenomedullin is a potent vasodilator and can inhibit pituitary ACTH secretion. ADM (1-52),ADM(1-52),Adrenomedullin (1-52),PAMP(1-20)NH2,Proadrenomedullin (1-20),Proadrenomedullin N-Terminal 20 Peptide,Proadrenomedullin N Terminal 20 Peptide

Related Publications

F W Hanna, and K D Buchanan
Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.
March 2008, British journal of pharmacology,
F W Hanna, and K D Buchanan
Adrenomedullin, a multifunctional regulatory peptide.
April 2000, Endocrine reviews,
F W Hanna, and K D Buchanan
Studies on adrenomedullin: a novel hypotensive peptide.
October 1995, Chinese medical journal,
F W Hanna, and K D Buchanan
Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage.
January 2002, Circulation,
F W Hanna, and K D Buchanan
Pulmonary vasodilation to adrenomedullin: a novel peptide in humans.
June 1995, The American journal of physiology,
F W Hanna, and K D Buchanan
Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis.
April 1996, The Journal of clinical endocrinology and metabolism,
F W Hanna, and K D Buchanan
Coronary vasodilatory response to a novel peptide, adrenomedullin 2.
December 2004, Clinical and experimental pharmacology & physiology,
F W Hanna, and K D Buchanan
Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.
April 1993, Biochemical and biophysical research communications,
F W Hanna, and K D Buchanan
A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotropin release.
May 1995, Endocrinology,
F W Hanna, and K D Buchanan
Endothelin: a new cardiovascular regulatory peptide.
November 1990, Mayo Clinic proceedings,
Copied contents to your clipboard!